[go: up one dir, main page]

MX2018005439A - Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas. - Google Patents

Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas.

Info

Publication number
MX2018005439A
MX2018005439A MX2018005439A MX2018005439A MX2018005439A MX 2018005439 A MX2018005439 A MX 2018005439A MX 2018005439 A MX2018005439 A MX 2018005439A MX 2018005439 A MX2018005439 A MX 2018005439A MX 2018005439 A MX2018005439 A MX 2018005439A
Authority
MX
Mexico
Prior art keywords
compounds
addiction
abuse
oxadiazoespirical
drugs
Prior art date
Application number
MX2018005439A
Other languages
English (en)
Other versions
MX384637B (es
Inventor
Almansa Rosales Carmen
ALEGRET-MOLINA Carlos
Virgili-Bernado Marina
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MX2018005439A publication Critical patent/MX2018005439A/es
Publication of MX384637B publication Critical patent/MX384637B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a compuestos con actividad farmacológica contra el receptor sigma (s), y más en particular a compuestos oxadiazaespíricos con dicha actividad farmacológica, a procesos de preparación de tales compuestos, a composiciones farmacéuticas que los comprenden y a su uso en terapia, en particular contra el abuso y la adicción a las drogas.
MX2018005439A 2015-11-16 2016-11-15 Compuestos oxadiazoespíricos para el tratamiento del abuso y la adicción a las drogas. MX384637B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382566 2015-11-16
PCT/EP2016/001907 WO2017084752A1 (en) 2015-11-16 2016-11-15 Oxadiazaspiro compounds for the treatment of drug abuse and addiction

Publications (2)

Publication Number Publication Date
MX2018005439A true MX2018005439A (es) 2018-11-09
MX384637B MX384637B (es) 2025-03-14

Family

ID=54707728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005439A MX384637B (es) 2015-11-16 2016-11-15 Compuestos oxadiazoespíricos para el tratamiento del abuso y la adicción a las drogas.

Country Status (29)

Country Link
US (2) US10927128B2 (es)
EP (1) EP3377500B1 (es)
JP (1) JP6884974B2 (es)
KR (2) KR20180080327A (es)
CN (1) CN108349999A (es)
AR (1) AR106697A1 (es)
AU (1) AU2016356488B2 (es)
CO (1) CO2018004665A2 (es)
DK (1) DK3377500T3 (es)
ES (1) ES2932000T3 (es)
HR (1) HRP20221343T1 (es)
HU (1) HUE060275T2 (es)
IL (1) IL259035B (es)
LT (1) LT3377500T (es)
MA (1) MA43250B1 (es)
MX (1) MX384637B (es)
MY (1) MY193423A (es)
PH (1) PH12018500814A1 (es)
PL (1) PL3377500T3 (es)
PT (1) PT3377500T (es)
RS (1) RS63734B1 (es)
SG (1) SG11201803153RA (es)
SI (1) SI3377500T1 (es)
SM (1) SMT202200460T1 (es)
TN (1) TN2018000122A1 (es)
TW (1) TWI756196B (es)
UA (1) UA123775C2 (es)
WO (1) WO2017084752A1 (es)
ZA (1) ZA201802845B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201803153RA (en) 2015-11-16 2018-06-28 Esteve Labor Dr Oxadiazaspiro compounds for the treatment of drug abuse and addiction
WO2020157026A1 (en) * 2019-01-28 2020-08-06 Esteve Pharmaceuticals, S.A. Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
IL310950A (en) 2021-09-20 2024-04-01 Esteve Pharmaceuticals Sa Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244961A (en) * 1978-10-26 1981-01-13 Syntex (U.S.A.) Inc. 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
RU2006132465A (ru) * 2004-02-10 2008-03-20 Ф.Хоффманн-Ля Рош Аг (Ch) Модуляторы хемокинового рецептора ccr5
NZ549567A (en) 2004-03-03 2009-10-30 Vital Health Sciences Pty Ltd Formulations comprising a tocopheryl phosphate tertiary amine alkaloid complex
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
WO2006022454A1 (ja) * 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
CN101228127B (zh) * 2005-05-30 2012-05-16 Msdk.K.公司 哌啶衍生物
CN101203567A (zh) * 2005-06-07 2008-06-18 西巴特殊化学品控股有限公司 抗刮擦聚烯烃
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
EP1940821B1 (de) 2005-10-19 2013-03-20 Grünenthal GmbH Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
US8877779B2 (en) 2007-03-01 2014-11-04 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) * 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
JP2010538003A (ja) 2007-08-29 2010-12-09 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
UA100400C2 (uk) 2008-02-06 2012-12-25 Астразенека Аб Похідні спіроциклічних амідів
EP2108643A1 (en) * 2008-04-10 2009-10-14 Laboratorios Del. Dr. Esteve, S.A. 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist
GB201016912D0 (en) * 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
AU2012229187B2 (en) 2011-03-14 2016-11-10 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
WO2013052716A1 (en) * 2011-10-07 2013-04-11 Glaxosmithkline Llc Fatty acid synthase inhibitors
WO2013115294A1 (ja) * 2012-01-31 2013-08-08 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
TWI685497B (zh) * 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
US10513518B2 (en) * 2015-01-29 2019-12-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
SG11201803153RA (en) 2015-11-16 2018-06-28 Esteve Labor Dr Oxadiazaspiro compounds for the treatment of drug abuse and addiction

Also Published As

Publication number Publication date
RU2018120748A (ru) 2019-12-05
JP2018533598A (ja) 2018-11-15
EP3377500A1 (en) 2018-09-26
TW201731854A (zh) 2017-09-16
UA123775C2 (uk) 2021-06-02
MY193423A (en) 2022-10-12
US11649248B2 (en) 2023-05-16
DK3377500T3 (da) 2022-11-21
TWI756196B (zh) 2022-03-01
TN2018000122A1 (en) 2019-10-04
AR106697A1 (es) 2018-02-07
SI3377500T1 (sl) 2023-02-28
PL3377500T3 (pl) 2023-01-23
EP3377500B1 (en) 2022-10-19
MA43250B1 (fr) 2022-12-30
LT3377500T (lt) 2022-12-12
KR20180080327A (ko) 2018-07-11
US10927128B2 (en) 2021-02-23
PT3377500T (pt) 2022-11-25
SMT202200460T1 (it) 2023-01-13
AU2016356488A1 (en) 2018-05-10
MX384637B (es) 2025-03-14
HRP20221343T1 (hr) 2022-12-23
CA3002286A1 (en) 2017-05-26
CO2018004665A2 (es) 2018-07-19
CN108349999A (zh) 2018-07-31
US20210115062A1 (en) 2021-04-22
KR20250069710A (ko) 2025-05-19
IL259035B (en) 2021-06-30
RS63734B1 (sr) 2022-12-30
BR112018009279A8 (pt) 2019-02-26
SG11201803153RA (en) 2018-06-28
ZA201802845B (en) 2021-10-27
US20180327422A1 (en) 2018-11-15
WO2017084752A1 (en) 2017-05-26
RU2018120748A3 (es) 2020-02-07
HUE060275T2 (hu) 2023-02-28
ES2932000T3 (es) 2023-01-09
PH12018500814A1 (en) 2018-10-29
AU2016356488B2 (en) 2020-10-22
BR112018009279A2 (pt) 2018-11-06
IL259035A (en) 2018-06-28
MA43250A (fr) 2021-04-14
JP6884974B2 (ja) 2021-06-09

Similar Documents

Publication Publication Date Title
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CR20150326A (es) Inhibidores de autotaxina
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
MX2016007410A (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2018005439A (es) Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas.
MX2017009608A (es) Compuestos anticancerigenos.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
CO2018011797A2 (es) Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor
GT201600190A (es) Compuestos químicos
ECSP17008187A (es) Formas de dosificación farmacéutica
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
UY36474A (es) Método para producir liposomas que contienen un ingrediente farmacéutico activo
ES2472040R1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria